After histological confirmation, TNM staging is performed and tumour subtypes are defined by immunohistochemical (IH), with hormone therapy for patients with luminal tumours [5], and monoclonal antibodies in those with Human Epidermal Receptor type 2 (HER2) overexpression [6], in addition to chemotherapy. The gene discussed is ERBB2; the disease is neoplasm.